Aller au contenu principal
xMedica

NCT07439653ClinicalTrials.gov

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Phase 1 / Phase 2155 participants recherchés9 sites1 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-02-27; recorded start 2026-03-31
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 9 other studies in this databaseCounted from the lead sponsor named in the record (TORL Biotherapeutics, LLC)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Non-randomised allocation

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 3 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleSMALL

A small study: 155 participants (target), run at 9 sites.

How this score is built
  • Enrolment21/40

    155 participants (target)

  • Site count6/25

    3 sites

  • Country count0/15

    Single country

  • Planned duration9/10

    Planned over about 43 months

  • Sponsor scale3/10

    TORL Biotherapeutics, LLC has led 10 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Affections

  • Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT. * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. * At least 1 measurable lesion per Lugano criteria. * Tumor tissue is available. * Adequate organ function Exclusion Criteria: * T-cell lymphoma * CLL or SL * Burkitt lymphoma and high-grade B-cell lymphoma * CNS involvement * Peripheral neuropathy \> Grade 2 * Uncontrolled medical conditions * Viral infections

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 1 / Phase 2
RépartitionNon randomisée
Modèle d'interventionSEQUENTIAL
Objectif principalTREATMENT
InsuNONE (0)
Recrutement155 participants recherchés

Promoteur et collaborateurs

  • TORL Biotherapeutics, LLC Promoteur

Groupes et interventions

  • Part 1: Monotherapy Dose EscalationEXPERIMENTAL

    TORL-5-700 Administered once every three weeks

  • Part 2: Monotherapy ExpansionEXPERIMENTAL

    TORL-5-700 at MTD/RP2D Administered once every three weeks

  • Part 3: Combination EvaluationEXPERIMENTAL

    TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent

Interventions

  • Médicament TORL-5-700

    Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks

  • Médicament TORL-5-700 at MTD/RP2D

    Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks

  • Médicament TORL-5-700 at MTD/RP2D in combination with another agent

    Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent

Critères de jugement

  1. Critère de jugement principal

    Evaluate the safety of TORL-5-700 as a monotherapy

    Assessment of adverse events according to NCI-CTCAE Version 5.0

    Délai though study completion, an average of 2.5 years

  2. Critère de jugement principal

    Assess the antitumor activity of TORL-5-700 as monotherapy

    Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria

    Délai though study completion, an average of 2.5 years

  3. Critère de jugement principal

    Evaluate the safety of TORL-5-700 in combination with other agents

    Assessment of adverse events according to NCI-CTCAE Version 5.0

    Délai though study completion, an average of 2.5 years

  4. Critère de jugement principal

    Determine the Maximum Tolerated Dose (MTD)

    Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)

    Délai 21 days from the start of treatment

  5. Critère de jugement principal

    Determine the Recommended Phase 2 Dose (RP2D)

    Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities

    Délai 21 days from the start of treatment

  6. Critère de jugement secondaire

    Maximum Serum Concentration of TORL-5-700 (Cmax)

    Pk assessment

    Délai though end of study treatment, an average of 5 months

  7. Critère de jugement secondaire

    Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents

    Pk assessment

    Délai though end of study treatment, an average of 5 months

  8. Critère de jugement secondaire

    Terminal Half-life (t1/2) of Serum TORL-5-700

    Pk assessment

    Délai though end of study treatment, an average of 5 months

  9. Critère de jugement secondaire

    Terminal Half-life (t1/2) of Serum TORL-5-700 in combination with other agents

    Pk assessment

    Délai though end of study treatment, an average of 5 months

  10. Critère de jugement secondaire

    Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration

    Pk assessment

    Délai though end of study treatment, an average of 5 months

  11. Critère de jugement secondaire

    Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents

    Pk assessment

    Délai though end of study treatment, an average of 5 months

  12. Critère de jugement secondaire

    Clearance (CL) of TORL-5-700

    Pk assessment

    Délai though end of study treatment, an average of 5 months

  13. Critère de jugement secondaire

    Clearance (CL) of TORL-5-700 in combination with other agents

    Pk assessment

    Délai though end of study treatment, an average of 5 months

  14. Critère de jugement secondaire

    Volume of distribution of TORL-5-700

    PK assessment

    Délai though end of study treatment, an average of 5 months

  15. Critère de jugement secondaire

    Volume of distribution of TORL-5-700 in combination with other agents

    PK assessment

    Délai though end of study treatment, an average of 5 months

  16. Critère de jugement secondaire

    Immunogenicity of TORL-5-700

    Immunogenicity will be measured by incidence of treatment emergent ADAs

    Délai though end of study treatment, an average of 5 months

  17. Critère de jugement secondaire

    Immunogenicity of TORL-5-700 in combination with other agents

    Immunogenicity will be measured by incidence of treatment emergent ADAs

    Délai though end of study treatment, an average of 5 months

  18. Critère de jugement secondaire

    Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents

    Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria

    Délai though study completion, an average of 2.5 years

Dates

Dates
Date de début31 mars 2026 (réelle)
Achèvement principal31 mars 2029 (estimée)
Achèvement30 septembre 2029 (estimée)
Première publication27 février 2026 (réelle)
Dernière mise à jour28 septembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisaoût 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

9 sites sont en recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
University of Texas Southwestern Medical CenterDallasTexasEn recrutement
Providence Medical FoundationFullertonCaliforniaEn recrutement
University of Iowa Health CareIowa CityIowaEn recrutement
Cancer and Blood Specialty Clinic, Los AlamitosLos AlamitosCaliforniaEn recrutement
University of California Miami, Sylvester Comprehensive Cancer CenterMiamiFloridaEn recrutement
Sarah Cannon Research InstituteNashvilleTennesseeEn recrutement
UCLASanta MonicaCaliforniaEn recrutement
Stanford UniversityStanfordCaliforniaEn recrutement
Cancer Center of Kansas, WichitaWichitaKansasEn recrutement

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 28 septembre 2026

    Site ajouté

    3 sites added (9 total)

    69

  2. 24 août 2026

    Site ajouté

    3 sites added (6 total)

    36